Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch [Yahoo! Finance]
Olema Pharmaceuticals, Inc. (OLMA)
Company Research
Source: Yahoo! Finance
Cormorant Asset Management initiated a new position in Olema Pharmaceuticals (NASDAQ:OLMA) , buying 2,750,000 shares worth $68.75 million in the fourth quarter, according to a February 17, 2026, SEC filing. What happened Cormorant Asset Management disclosed a new position in Olema Pharmaceuticals in a quarterly U.S. Securities and Exchange Commission filing dated February 17, 2026. The fund acquired 2,750,000 shares worth $68.75 million at the end of the quarterr. What else to know This was a new position for Cormorant Asset Management, representing 3.18% of 13F reportable AUM as of December 31, 2025. Top holdings after the filing: NASDAQ:PRAX: $280.00 million (15.9% of AUM) NASDAQ:BBOT: $223.84 million (12.7% of AUM) NASDAQ:ABVX: $182.05 million (10.3% of AUM) NASDAQ:EYPT: $151.00 million (8.6% of AUM) NASDAQ:RAPP: $91.85 million (5.2% of AUM) As of Monday, Olema shares were priced at $16.60, up 276% over the past year and well outperforming the S&P 500's rough
Show less
Read more
Impact Snapshot
Event Time:
OLMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OLMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OLMA alerts
High impacting Olema Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
OLMA
News
- Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual MeetingGlobeNewswire
- Olema Pharmaceuticals (OLMA) had its price target raised by Citigroup Inc. from $60.00 to $62.00. They now have a "buy" rating on the stock.MarketBeat
- Olema Pharmaceuticals (OLMA) had its price target lowered by Guggenheim from $40.00 to $38.00. They now have a "buy" rating on the stock.MarketBeat
- Olema Pharmaceuticals GAAP EPS of -$0.50 beats by $0.01 [Seeking Alpha]Seeking Alpha
- Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating ResultsGlobeNewswire
OLMA
Earnings
- 3/16/26 - Beat
OLMA
Sec Filings
- 3/16/26 - Form 144
- 3/16/26 - Form 144
- 3/16/26 - Form S-8
- OLMA's page on the SEC website